Clinical Trials Logo

Filter by:
NCT ID: NCT00790088 Completed - Clinical trials for Diabetes Mellitus, Type 1

INTERPRET - International Report on Routine Practice of Sensor-enabled Pump Therapy

Start date: February 2009
Phase:
Study type: Observational

The aim of the project is to document the international routine practice in sensor usage in patients treated with sensor-augmented pump therapy and to assess which variables (e.g. training of patients, frequency of sensor usage etc) are associated with an improvement in clinical outcome(s) from the start of the sensor use to the end of the follow-up period.

NCT ID: NCT00790036 Completed - Clinical trials for Diffuse Large B-cell Lymphoma

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

PILLAR2
Start date: July 2009
Phase: Phase 3
Study type: Interventional

Phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapy

NCT ID: NCT00789854 Completed - Clinical trials for Major Depressive Disorder

Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients

RUBY
Start date: November 2008
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to evaluate the efficacy of Quetiapine extended release (XR) in combination with an selective serotonin reuptake inhibitor (SSRI) or Venlafaxine versus Lithium in combination with an selective serotonin reuptake inhibitor or Venlafaxine versus Quetiapine extended release monotherapy in subjects with treatment resistant depression as assessed by the changes from randomisation to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. As an independent objective, the primary objective will also be evaluated in two subgroups of patients: (1) patients who were resistant to two previous antidepressant therapies and (2) in the subgroup of patients with one previous failure.

NCT ID: NCT00789191 Completed - Clinical trials for Diabetes Mellitus, Type 2

Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes

Start date: November 2008
Phase: Phase 3
Study type: Interventional

This trial is conducted in Asia, Europe and North America. This trial aims for comparison of the effect on the glycemic control in subjects with type 2 diabetes of basal insulin analogue with one oral anti-diabetic drug (OAD) versus oral anti-diabetic drug alone.

NCT ID: NCT00789035 Completed - Clinical trials for Diabetes Mellitus, Type 2

12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients

Start date: October 2008
Phase: Phase 2
Study type: Interventional

The objective is to investigate the efficacy, safety and pharmacokinetics of three different doses of BI 10773 compared to placebo given for 12 weeks in patients with type 2 diabetes mellitus with insufficient glycemic control. In addition an open-label metformin arm will be assessed

NCT ID: NCT00787657 Completed - Clinical trials for Relapsing Remitting Multiple Sclerosis (RRMS)

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

BEACON
Start date: June 2008
Phase: N/A
Study type: Observational

- The Study analyses the influence of selected factors on adherence to Betaferon treatment in patients with early multiple sclerosis (MS). The Investigator will document the relevant medical data regarding multiple sclerosis at every hospital visit, the patient will fill in two questionnaires at every visit: one about coping with the disease and the other about anxiety and depression. - The Study particularly looks at the role of the support of the patient given by the multiple sclerosis nurses.The nurse will provide additional standardised information at start of treatment and will regularly phone the patient to ask standardised questions about the general condition with regard to the treatment, the disease and social support. At the end of the Study it will be assessed if the supportive measures and the standards in terms of adherence management in the hospital have some influence to increase long-term treatment adherence.

NCT ID: NCT00787202 Completed - Ulcerative Colitis Clinical Trials

A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.

Start date: December 2008
Phase: Phase 2
Study type: Interventional

The hypothesis of the study is that at least one dose of CP 690 550 is superior to placebo (inactive drug) in inducing remission in patients with moderate to severe ulcerative colitis.

NCT ID: NCT00785928 Completed - Clinical trials for Rheumatoid Arthritis

A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy

Start date: October 2008
Phase: Phase 2
Study type: Interventional

To assess the efficacy of LY2127399 versus placebo using American College of Rheumatology (ACR)50 response scale at 24 weeks

NCT ID: NCT00785785 Completed - Clinical trials for Gastrointestinal Stromal Tumor (GIST)

A Study of Nilotinib Versus Imatinib in GIST Patients

ENESTg1
Start date: March 2009
Phase: Phase 3
Study type: Interventional

This study will evaluate efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).

NCT ID: NCT00783510 Completed - Clinical trials for Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis (JIA) Registry

STRIVE
Start date: July 11, 2008
Phase:
Study type: Observational

This is a global registry, to evaluate the long-term safety of Humira® in patients with moderate to severe polyarticular Juvenile Idiopathic Arthritis (JIA), that are treated as recommended in the Humira® product label. Patients treated with MTX will be considered a reference group. Patients will be followed in both the Humira® and Methotrexate (MTX) arms for 10 years from the enrollment date into one of the treatment arms.